Market Closed -
Nasdaq
04:00:00 2024-09-05 pm EDT
5-day change
1st Jan Change
1,150.56 USD
-2.44%
-2.41%
+31.00%
Capitalization
124B
P/E ratio 2024 *
30.9x
P/E ratio 2025 *
28.7x Enterprise value
115B
EV / Sales 2024 *
8.12x
EV / Sales 2025 *
7.18x Free-Float
79.08%
Yield 2024 *
-
Yield 2025 *
-
Duration
1 day 1 week 1 month 3 months 6 months 1 year 5 years 10 years
Period
5 minutes 15 minutes 30 minutes 1 hour 1 day 1 week 1 month 1 year
Style
CandleStick End-of-day OHLC Mountain
Dynamic Chart
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,178,730, According to a Recent SEC Filing
Sep. 05
MT
Transcript : Regeneron Pharmaceuticals, Inc. Presents at Wells Fargo 2024 Healthcare Conference, Sep-05-2024 12:45 PM
Sep. 05
RBC Capital Adjusts Price Target on Regeneron Pharmaceuticals to $1,250 From $1,240
Sep. 05
MT
Transcript : Regeneron Pharmaceuticals, Inc. Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-04-2024 11:30 AM
Sep. 04
Sonoma Biotherapeutics Receives $45 Million Milestone Payment from Regeneron Under Ongoing Collaboration
Sep. 04
CI
Regeneron Pharmaceuticals Insider Sold Shares Worth $6,846,262, According to a Recent SEC Filing
Aug. 29
MT
Regeneron Pharmaceuticals Gets European Commission Approval for Ordspono
Aug. 26
MT
Regeneron Pharmaceuticals, Inc Announces Ordspono (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Aug. 26
CI
Piper Sandler Adjusts Price Target on Regeneron Pharmaceuticals to $1,242 From $1,166, Maintains Overweight Rating
Aug. 23
MT
Global markets live: Novo Nordisk, Walmart, Target, Keysight Technologies, Coty...
Aug. 21
All eyes on the Fed's minutes
Aug. 21
Regeneron Pharmaceuticals Says FDA Approval of Multiple Myeloma Treatment Slowed Over Factory Concerns
Aug. 21
MT
Regeneron Provides Update on Biologics License Application for Linvoseltamab
Aug. 20
CI
More news
RBC Capital Adjusts Price Target on Regeneron Pharmaceuticals to $1,250 From $1,240
Sep. 05
MT
Piper Sandler Adjusts Price Target on Regeneron Pharmaceuticals to $1,242 From $1,166, Maintains Overweight Rating
Aug. 23
MT
Global markets live: Novo Nordisk, Walmart, Target, Keysight Technologies, Coty...
Aug. 21
Argus Raises Price Target on Regeneron Pharmaceuticals to $1,175 From $1,170
Aug. 08
MT
Deutsche Bank Raises Price Target on Regeneron Pharmaceuticals to $990 From $870
Aug. 02
MT
More recommendations
1 day -2.44%
1 week -2.41%
Current month -2.88%
1 month +7.40%
3 months +14.38%
6 months +19.20%
Current year +31.00%
More quotes
Director
Title Age Since
Founder
64
88-01-07
Chief Executive Officer
71
88-01-07
Director of Finance/CFO
53
02-12-31
Manager
Title Age Since
Chief Executive Officer
71
88-01-07
Director/Board Member
83
91-05-31
Director/Board Member
83
91-05-31
More insiders
2024 * 2025 * Net sales
14.15B
15.37B
Net income
4.23B
4.43B
Net Debt
-9.25B
-13.9B
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows:
- revenues from product sales (56.6%);
- revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%);
- other (3%): primarily revenues from sales of technology licenses and subcontracted research services.
At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.
More about the company
Date
Price
Change
Volume
24-09-05
1,150.56
$
-2.44%
534,411
24-09-04
1,179.37
$
+0.90%
333,049
24-09-03
1,168.81
$
-1.34%
579,321
24-08-30
1,184.69
$
+0.49%
405,354
24-08-29
1,178.93
$
-1.70%
538,650
Delayed Quote
Nasdaq, September 05, 2024 at 04:00 pm EDT
More quotes
Last Close Price
1,150.56 USD
Average target price
1,153.73 USD
Spread / Average Target
+0.28%
Consensus
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1